GSK plc has high hopes for depemokimab, having previously suggested that it could bring in peak sales of more than £3bn ($3.8bn). For that to happen the ultra-long-acting IL-5 inhibitor will have to hit in a suite of late-stage trials, but the UK group is off to a good start with the results of two asthma studies.
Key Takeaways
- GSK’s IL-5 inhibitor depemokimab has hit in two Phase III trials in severe asthma
- If depemokimab can match the efficacy of existing anti-IL-5s its less frequent dosing...
The twin Phase III trials SWIFT-1 and SWIFT-2, which assessed depemokimab in patients with severe asthma with type 2 inflammation characterized by blood eosinophil count, were disclosed as successes today....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
